Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
Alshamleh I, Kurrle N, Makowka P, Bhayadia R, Kumar R, Süsser S, Seibert M, Ludig D, Wolf S, Koschade SE, Stoschek K, Kreitz J, Fuhrmann DC, Toenges R, Notaro M, Comoglio F, Schuringa JJ, Berg T, Brüne B, Krause DS, Klusmann JH, Oellerich T, Schnütgen F, Schwalbe H, Serve H. Alshamleh I, et al. Among authors: schuringa jj. Leukemia. 2023 Dec;37(12):2367-2382. doi: 10.1038/s41375-023-02041-5. Epub 2023 Nov 7. Leukemia. 2023. PMID: 37935978 Free PMC article.
Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia.
Hogeling SM, Lê DM, La Rose N, Kwon MC, Wierenga ATJ, Van den Heuvel FAJ, Van den Boom V, Kuchnio A, Philippar U, Huls G, Schuringa JJ. Hogeling SM, et al. Among authors: schuringa jj. Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.285616. Online ahead of print. Haematologica. 2024. PMID: 39704147 Free article.
Clonal hematopoiesis and myeloid skewing in older population-based individuals.
van Bergen MGJM, Kamphuis P, de Graaf AO, Salzbrunn JB, Koorenhof-Scheele TN, van Zeventer IA, Dinmohamed AG, Schuringa JJ, van der Reijden BA, Huls G, Jansen JH. van Bergen MGJM, et al. Among authors: schuringa jj. Am J Hematol. 2024 Dec;99(12):2402-2405. doi: 10.1002/ajh.27495. Epub 2024 Oct 21. Am J Hematol. 2024. PMID: 39429216 No abstract available.
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James SC, Atkinson S, Durko J, Wang LM, Campos J, Magee AMS, Woodley K, Austin MJ, Rio-Machin A, Casado P, Bewicke-Copley F, Rodriguez Blanco G, Pereira-Martins D, Oudejans L, Boet E, von Kriegsheim A, Schwaller J, Finch AJ, Patel B, Sarry JE, Tamburini J, Schuringa JJ, Hazlehurst L, Copland Iii JA, Yuneva M, Peck B, Cutillas P, Fitzgibbon J, Rouault-Pierre K, Kranc K, Gallipoli P. Dembitz V, et al. Among authors: schuringa jj. Leukemia. 2024 Nov;38(11):2395-2409. doi: 10.1038/s41375-024-02390-9. Epub 2024 Aug 26. Leukemia. 2024. PMID: 39187579 Free PMC article.
Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry.
Kleftogiannis D, Gavasso S, Tislevoll BS, van der Meer N, Motzfeldt IKF, Hellesøy M, Gullaksen SE, Griessinger E, Fagerholt O, Lenartova A, Fløisand Y, Schuringa JJ, Gjertsen BT, Jonassen I. Kleftogiannis D, et al. Among authors: schuringa jj. iScience. 2024 Jun 12;27(7):110261. doi: 10.1016/j.isci.2024.110261. eCollection 2024 Jul 19. iScience. 2024. PMID: 39021803 Free PMC article.
Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia.
Salustiano-Bandeira ML, Moreira-Aguiar A, Pereira-Martins DA, Coelho-Silva JL, Weinhäuser I, França-Neto PL, Lima AS, Lima AS, Baccarin AR, Silva FB, de Melo MA, Niemann FS, Nardinelli L, Ortiz Rojas CA, Duarte BK, Araujo AS, Azevedo EA, Morais CN, Figueiredo-Pontes LL, Schuringa JJ, Huls G, Bendit I, Rego EM, Olalla Saad ST, Traina F, Bezerra MA, Lucena-Araujo AR. Salustiano-Bandeira ML, et al. Among authors: schuringa jj. Blood Cancer J. 2024 Jun 24;14(1):102. doi: 10.1038/s41408-024-01086-8. Blood Cancer J. 2024. PMID: 38914584 Free PMC article. No abstract available.
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, Marien A, Goffin D, Wenge DV, Yue H, Cutler JA, Jin C, Perner F, Hogeling SM, Shaffer PL, Jacobs F, Vinken P, Cai W, Keersmaekers V, Eyassu F, Bhogal B, Verstraeten K, El Ashkar S, Perry JA, Jayaguru P, Barreyro L, Kuchnio A, Darville N, Krosky D, Urbanietz G, Verbist B, Edwards JP, Cowley GS, Kirkpatrick R, Steele R, Ferrante L, Guttke C, Daskalakis N, Pietsch EC, Wilson DM, Attar R, Elsayed Y, Fischer ES, Schuringa JJ, Armstrong SA, Packman K, Philippar U. Kwon MC, et al. Among authors: schuringa jj. Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480. Blood. 2024. PMID: 38905635 Free PMC article.
146 results